BELVEDERE, RAFFAELLA
 Distribuzione geografica
Continente #
NA - Nord America 857
EU - Europa 366
AS - Asia 192
Totale 1415
Nazione #
US - Stati Uniti d'America 856
IT - Italia 248
VN - Vietnam 104
CN - Cina 60
UA - Ucraina 38
IE - Irlanda 35
TR - Turchia 24
DE - Germania 20
SE - Svezia 10
FI - Finlandia 8
HK - Hong Kong 3
FR - Francia 2
CA - Canada 1
ES - Italia 1
GB - Regno Unito 1
HU - Ungheria 1
IM - Isola di Man 1
JP - Giappone 1
RO - Romania 1
Totale 1415
Città #
Chandler 243
Ann Arbor 131
Princeton 106
Dong Ket 104
Salerno 93
Houston 87
Jacksonville 63
Woodbridge 52
Wilmington 47
Dublin 35
Izmir 24
Andover 20
Nanjing 19
Dearborn 14
Beijing 13
Fisciano 13
Redwood City 11
Falls Church 9
Boardman 8
Montecorvino Pugliano 7
Nanchang 7
Naples 7
Napoli 7
Pellezzano 7
Nocera Inferiore 6
Seattle 6
Bologna 5
Mestre 5
Ashburn 4
Fairfield 4
Shenyang 4
Cambridge 3
Carbonia 3
Cava De' Tirreni 3
Central 3
Norwalk 3
Pomigliano d'Arco 3
Atella 2
Capaccio 2
Changsha 2
Düsseldorf 2
Falkenstein 2
Forino 2
Hanover 2
Hebei 2
Jinan 2
Piemonte 2
San Diego 2
Santa Clara 2
Yellow Springs 2
Zhengzhou 2
Acerra 1
Bari 1
Battipaglia 1
Benevento 1
Budapest 1
Calvizzano 1
Casavatore 1
Douglas 1
Florence 1
Guangzhou 1
Hefei 1
Helsinki 1
Jiaxing 1
Landshut 1
Lanzhou 1
Limbiate 1
London 1
Madrid 1
Nagold 1
Nettuno 1
New York 1
Olbia 1
Ottawa 1
Pisa 1
Putian 1
San Giuliano Milanese 1
Shanghai 1
Spinea 1
Stella Cilento 1
Timisoara 1
Tokyo 1
Vertova 1
Villaricca 1
Walnut 1
Totale 1241
Nome #
Role of intracellular and extracellular annexin A1 in migration and invasion of human pancreatic carcinoma cells. 128
Annexin A1 Induces Skeletal Muscle Cell Migration Acting through Formyl Peptide Receptors. 103
Evaluation of in situ injectable hydrogels as controlled release device for ANXA1 derived peptide in wound healing 101
Annexin A1 contributes to pancreatic cancer cell phenotype, behaviour and metastatic potential independently of Formyl Peptide Receptor pathway 81
Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid 73
Annexin A1 N-Terminal Derived Peptide Ac2-26 Stimulates Fibroblast Migration in High Glucose Conditions. 71
Hypoxia regulates ANXA1 expression to support prostate cancer cell invasion and aggressiveness 69
Annexin A1 Contained in Extracellular Vesicles Promotes the Activation of Keratinocytes by Mesoglycan Effects: An Autocrine Loop Through FPRs 60
Effects of Prisma® Skin dermal regeneration device containing glycosaminoglycans on human keratinocytes and fibroblasts 56
Annexin A1 May Induce Pancreatic Cancer Progression as a Key Player of Extracellular Vesicles Effects as Evidenced in the In Vitro MIA PaCa-2 Model System 56
ROLE OF ANNEXIN A1 IN MIGRATION OF HUMAN PANCREATIC CARCINOMA CELL LINES 55
COMPOSIZIONE PER IL TRATTAMENTO DI LESIONI CUTANEE 50
The pharmaceutical device prisma® skin promotes in vitro angiogenesis through endothelial to mesenchymal transition during skin wound healing 47
LGP1 STIMULATES APOPTOSIS IN U937 ASSOCIATED TO INCREASED ANNEXIN A1 PROTEIN EXPRESSION 42
Cocoa Extract Provides Protection against 6-OHDA Toxicity in SH-SY5Y Dopaminergic Neurons by Targeting PERK 41
Mesoglycan induces keratinocyte activation by triggering syndecan‐4 pathway and the formation of the annexin A1/S100A11 complex 41
TFF1 Promotes EMT-Like Changes through an Auto-Induction Mechanism 40
Annexin A1 Released in Extracellular Vesicles by Pancreatic Cancer Cells Activates Components of the Tumor Microenvironment, through Interaction with the Formyl-Peptide Receptors 38
miR-196a Is Able to Restore the Aggressive Phenotype of Annexin A1 Knock-Out in Pancreatic Cancer Cells by CRISPR/Cas9 Genome Editing 33
Mesoglycan induces the secretion of microvesicles by keratinocytes able to activate human fibroblasts and endothelial cells: A novel mechanism in skin wound healing 33
Supercritical impregnation of mesoglycan into calcium alginate aerogel for wound healing 28
Mesoglycan exerts its fibrinolytic effect through the activation of annexin A2 27
Novel insights on the molecular mechanism of action of the anti-angiogenic pyrazolyl-urea GeGe-3 by functional proteomics 26
The procoagulant activity of emoxilane®: A new appealing therapeutic use in epistaxis of the combination of sodium hyaluronate, silver salt, α-tocopherol and d-panthenol 26
PCL/Mesoglycan Devices Obtained by Supercritical Foaming and Impregnation 25
A new pharmaceutical device containing mesoglycan modulates fibroblasts function in vivo 25
Heparan sulfate binds the extracellular Annexin A1 and blocks its effects on pancreatic cancer cells 24
The promising pro-healing role of the association of mesoglycan and lactoferrin on skin lesions 23
Mesoglycan connects Syndecan-4 and VEGFR2 through Annexin A1 and formyl peptide receptors to promote angiogenesis in vitro 22
Anxa1 contained in evs regulates macrophage polarization in tumor microenvironment and promotes pancreatic cancer progression and metastasis 20
The pyrazolyl-urea gege3 inhibits the activity of ANXA1 in the angiogenesis induced by the pancreatic cancer derived EVs 16
Drug affinity-responsive target stability unveils filamins as biological targets for artemetin, an anti-cancer flavonoid 16
Plant hairy roots for the production of extracellular vesicles with antitumor bioactivity 15
The combination of mesoglycan and VEGF promotes skin wound repair by enhancing the activation of endothelial cells and fibroblasts and their cross-talk 9
Role of Intracellular and Extracellular Annexin A1 in MIA PaCa-2 Spheroids Formation and Drug Sensitivity 6
Production of Mesoglycan/PCL Based Composites through Supercritical Impregnation 3
Totale 1529
Categoria #
all - tutte 2722
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2722


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201860 0000 00 040 36110
2018/2019120 11619 316 44 723351
2019/2020207 3624174 744 163 1119188
2020/2021254 48114 1911 3011 16219119
2021/2022247 70214 1014 910 31272598
2022/2023391 35923285 4595 07 0000
Totale 1529